Xenetic Biosciences (NASDAQ: XBIO) and Vital Therapies (NASDAQ:VTL) are both small-cap bio therapeutic drugs companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, institutional ownership and earnings.
Valuation and Earnings
This table compares Xenetic Biosciences and Vital Therapies’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Xenetic Biosciences||$3.00 million||6.45||-$54.20 million||($1.48)||-1.50|
|Vital Therapies||N/A||N/A||-$40.96 million||($1.34)||-4.33|
This table compares Xenetic Biosciences and Vital Therapies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations and price targets for Xenetic Biosciences and Vital Therapies, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Xenetic Biosciences presently has a consensus target price of $10.00, suggesting a potential upside of 350.45%. Vital Therapies has a consensus target price of $8.00, suggesting a potential upside of 37.93%. Given Xenetic Biosciences’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Xenetic Biosciences is more favorable than Vital Therapies.
Institutional and Insider Ownership
3.8% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 25.7% of Vital Therapies shares are held by institutional investors. 7.9% of Xenetic Biosciences shares are held by insiders. Comparatively, 32.6% of Vital Therapies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Xenetic Biosciences has a beta of 8.55, suggesting that its share price is 755% more volatile than the S&P 500. Comparatively, Vital Therapies has a beta of 5.3, suggesting that its share price is 430% more volatile than the S&P 500.
Vital Therapies beats Xenetic Biosciences on 6 of the 11 factors compared between the two stocks.
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company’s technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company’s lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.
Vital Therapies Company Profile
Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company’s ELAD System consists of approximately four disposable ELAD C3A cell cartridges.
Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.